Johnson & Johnson (NYSE:JNJ)‘s stock had its “hold” rating reiterated by analysts at Bank of America Corp. in a report issued on Monday. They currently have a $126.00 target price on the stock. Bank of America Corp.’s price objective would indicate a potential upside of 12.02% from the stock’s current price.

JNJ has been the subject of several other research reports. Credit Suisse Group AG reaffirmed a “neutral” rating and issued a $123.00 price objective on shares of Johnson & Johnson in a research note on Monday, September 19th. Vetr downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating and set a $119.60 target price on the stock. in a report on Tuesday, November 1st. Zacks Investment Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $139.00 target price on the stock in a report on Friday, August 5th. Jefferies Group lifted their target price on shares of Johnson & Johnson from $113.00 to $119.00 and gave the stock a “hold” rating in a report on Thursday, August 4th. Finally, Deutsche Bank AG reiterated a “buy” rating and issued a $142.00 target price on shares of Johnson & Johnson in a report on Friday, August 19th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $121.03.

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Shares of Johnson & Johnson (NYSE:JNJ) opened at 112.48 on Monday. Johnson & Johnson has a 52 week low of $94.28 and a 52 week high of $126.07. The firm has a market capitalization of $306.01 billion, a P/E ratio of 19.74 and a beta of 0.75. The stock’s 50 day moving average price is $115.85 and its 200 day moving average price is $118.43.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 18th. The company reported $1.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.66 by $0.02. The company earned $17.80 billion during the quarter, compared to analyst estimates of $17.71 billion. Johnson & Johnson had a net margin of 22.03% and a return on equity of 25.30%. During the same quarter last year, the business posted $1.49 EPS. The company’s revenue for the quarter was up 4.2% on a year-over-year basis. On average, analysts predict that Johnson & Johnson will post $6.72 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 6th. Investors of record on Tuesday, November 22nd will be paid a $0.80 dividend. The ex-dividend date of this dividend is Friday, November 18th. This represents a $3.20 dividend on an annualized basis and a yield of 2.84%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $0.29. Johnson & Johnson’s payout ratio is presently 56.64%.

COPYRIGHT VIOLATION WARNING: “Johnson & Johnson (JNJ) Rating Reiterated by Bank of America Corp.” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another website, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be read at https://www.thecerbatgem.com/2016/11/30/johnson-johnson-jnj-rating-reiterated-by-bank-of-america-corp.html.

In other Johnson & Johnson news, Director Charles Prince bought 875 shares of the stock in a transaction that occurred on Friday, October 21st. The shares were acquired at an average price of $114.11 per share, with a total value of $99,846.25. Following the completion of the purchase, the director now directly owns 26,520 shares in the company, valued at approximately $3,026,197.20. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.11% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently bought and sold shares of JNJ. Investec Asset Management North America Inc. raised its position in Johnson & Johnson by 20.4% in the first quarter. Investec Asset Management North America Inc. now owns 99,581 shares of the company’s stock worth $10,775,000 after buying an additional 16,869 shares during the period. Investec Asset Management LTD raised its position in Johnson & Johnson by 49.2% in the first quarter. Investec Asset Management LTD now owns 5,050,411 shares of the company’s stock worth $546,454,000 after buying an additional 1,665,644 shares during the period. Ropes Wealth Advisors LLC raised its position in Johnson & Johnson by 8.0% in the first quarter. Ropes Wealth Advisors LLC now owns 55,976 shares of the company’s stock worth $6,057,000 after buying an additional 4,161 shares during the period. A.R. Schmeidler & Co. Inc. raised its position in Johnson & Johnson by 2.9% in the first quarter. A.R. Schmeidler & Co. Inc. now owns 33,270 shares of the company’s stock worth $3,600,000 after buying an additional 953 shares during the period. Finally, Institutional & Family Asset Management LLC raised its position in Johnson & Johnson by 2.2% in the first quarter. Institutional & Family Asset Management LLC now owns 30,029 shares of the company’s stock worth $3,085,000 after buying an additional 640 shares during the period. 64.13% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

5 Day Chart for NYSE:JNJ

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.